Patient Square Capital LP Sells 34,738 Shares of Pharvaris (NASDAQ:PHVS)

Patient Square Capital LP cut its holdings in Pharvaris (NASDAQ:PHVS) by 14.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 207,603 shares of the company’s stock after selling 34,738 shares during the quarter. Pharvaris accounts for approximately 1.5% of Patient Square Capital LP’s investment portfolio, making the stock its 12th largest position. Patient Square Capital LP owned 0.40% of Pharvaris worth $3,980,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after buying an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Pharvaris in the 4th quarter valued at about $64,000. Barclays PLC purchased a new position in Pharvaris in the third quarter worth about $106,000. KLP Kapitalforvaltning AS purchased a new position in Pharvaris in the fourth quarter worth about $111,000. Finally, Legal & General Group Plc increased its stake in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock worth $189,000 after acquiring an additional 994 shares during the last quarter.

Pharvaris Trading Down 4.2%

PHVS stock opened at $16.11 on Wednesday. The stock has a market cap of $842.39 million, a PE ratio of -5.75 and a beta of -2.85. Pharvaris has a 12 month low of $11.51 and a 12 month high of $25.50. The company has a 50-day moving average price of $15.32 and a 200 day moving average price of $17.79.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.06. Sell-side analysts forecast that Pharvaris will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PHVS. JMP Securities raised their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st. Cantor Fitzgerald assumed coverage on Pharvaris in a report on Tuesday, April 29th. They set an “overweight” rating and a $28.00 price target on the stock.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.